Successful treatment of genital and facial psoriasis with tacrolimus ointment 0.1%

Drugs under Experimental and Clinical Research

Volumn 31, Issue 4, 2005, Pages 141-145

  Rallis, E ^a,e   Nasiopoulou, A ^a   Kouskoukis, C ^b   Roussaki Schulze, A ^c   Koumantaki, E ^d   Karpouzis, A ^b   Arvanitis, A ^a  

^a Veterans Administration Hospital (NIMTS)   (Greece)

^b DEMOCRITUS UNIVERSITY OF THRACE   (Greece)

^c GENERAL HOSPITAL OF LARISSA   (Greece)

^d UNIVERSITY OF ATHENS   (Greece)

^e NONE   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

TACROLIMUS;

ADULT; AGED; ARTICLE; CELL INFILTRATION; CLINICAL ARTICLE; CLINICAL TRIAL; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ERYTHEMA; FACE; FEMALE; FOLLOW UP; GENITAL SYSTEM; HUMAN; MALE; MULTICENTER STUDY; OPEN STUDY; PARAMETER; PSORIASIS; SCORING SYSTEM; SKIN DEFECT;

ADULT; FACE; FEMALE; GENITAL DISEASES, MALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; PSORIASIS; TACROLIMUS;

EID: 26244437068     PISSN: 03786501     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Marsland A.M., Griffiths C.E. The macrolide immunosuppressants in dermatology: Mechanisms of action. Eur. J. Dermatol., 12(6), 618, 2002.
2. Lazaroys M.C., Kerdel F.A. Topical tacrolimus. Protopic. Drugs Today, 38(1), 7, 2002.
3. Shainhouse T., Eichenfield L.F. Long-term safety of tacrolimus ointment in children treated for atopic dermatitis. Expert Opin. Drug Safety, 2(5), 457, 2003.
4. Ling M.R. Topical tacrolimus and pimecrolimus: Future directions. Semin. Cutan. Med. Surg., 20(4), 268, 2001.
5. Ruzicka T., Assmann T., Lebwohl M. Potential future dermatological indications for tacrolimus ointment. Eur. J. Dermatol., 13(4), 331, 2003.
6. Gupta A.K., Adamiak A., Chow M. Tacrolimus: A review of its use for the management of dermatoses. J. Eur. Acad. Dermatol. Venereol., 16(2), 100, 2002.
7. Kormeili T., Lowe N.J., Yamauchi P.S. Psoriasis: Immunopathogenesis and evolving immunomodulators and systemic therapies; U.S. experiences. Br. J. Dermatol., 151(1), 3, 2004.
8. Nickoloff B., Nestle O. Recent insights into the immunopathogenesis of psoriasis provide new therapeutic opportunities. J. Clin. Invest., 113, 1664, 2004.
9. Ortiz-Urda S., Rappersberger K. New immunosuppressive agents for treating psoriasis. Hautarzt, 54(3), 230, 2003.
10. Rappersberger K., Meingassner J.G., Fialla R., et al. Clearing of psoriasis by a novel immunosuppressive macrolide. J. Invest. Dermatol., 106(4), 701, 1996.
11. Scheinfeld N. The use of topical tacrolimus and pimecrolimus to treat psoriasis: A review. Dermatol. Online J., 10(1): 3, 2004.
12. Lebwohl M., Freeman A.K., Chapman M.S., et al. Tacrolimus ointment is effective for facial and intertriginous psoriasis. J. Am. Acad. Dermatol., 51(5), 723, 2004.
13. Freeman A.K., Linowski G.J., Brady C., et al. Tacrolimus ointment for the treatment of psoriasis on the face and intertriginous areas. J. Am. Acad. Dermatol., 48(4), 564, 2003.
14. Yamamoto T., Nishioka K. Topical tacrolimus: An effective therapy for facial psoriasis. Eur. J. Dermatol., 13(5), 471, 2003.
15. Bos J.D. Non-steroidal topical immunomodulators provide skin-selective, self-limiting treatment in atopic dermatitis. Eur. J. Dermatol., 13(5), 455, 2003.
16. Siddaiah N., Erickson Q., Miller G., Elston D.M. Tacrolimus-induced tinea incognito. Cutis, 73(4), 237, 2004.
17. Yamamoto T., Nishioka K. Deep dermatophytosis during topical tacrolimus therapy for psoriasis. Acta Derm. Venereol., 83(4), 291, 2003.
18. Sato Y., Shigeeda A., Ishizaki S., et al. A case of tinea capitis with a couple of nodular lesions possibly resulting from topical application of tacrolimus. Nippon Ishinkin Gakkai Zasshi, 45(3), 177, 2004.